22.2% Return Seen to Date on SmarTrend Cambrex Call (CBM)
Comtex SmarTrend(R) - Thu Dec 18, 9:54AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 months, Cambrex has returned 22.20% as of today's recent price of $23.53.
CBM: 21.62 (+0.37)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 21.85 (-0.07), MJN: 102.04 (+0.48), CBM: 21.62 (+0.37), SIAL: 137.16 (-0.01), USNA: 103.51 (+0.91), SYUT: 5.20 (+0.07), MTEX: 28.96 (unch), BCPC: 66.80 (-1.55)
Uptrend Call Working As Cambrex Stock Rises 22.0% (CBM)
Comtex SmarTrend(R) - Thu Dec 11, 9:37AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 21.99% as of today's recent price of $23.49.
CBM: 21.62 (+0.37)
Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Thu Dec 04, 12:40PM CST
Cambrex Corporation (NYSE: CBM, "Cambrex"
CBM: 21.62 (+0.37)
Shares of CBM Up 19.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 4:58PM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 19.86% as of today's recent price of $23.08.
CBM: 21.62 (+0.37)
Cambrex Shares Up 19.0% Since SmarTrend's Buy Recommendation (CBM)
Comtex SmarTrend(R) - Wed Nov 26, 11:12AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 4 weeks, Cambrex has returned 19.03% as of today's recent price of $22.92.
CBM: 21.62 (+0.37)
Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020 for the $190 Billion Industry
M2 - Thu Nov 20, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm7qx5/global_active) has announced the addition of the "Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020" report to their offering. The global Active Pharmaceutical Ingredient market is expected to reach a market size approximately $190 billion by 2020, growing at a CAGR of more than 6.5% from 2014 to 2020 API market is mainly driven by the factors such as patent expiration of major drugs, increased generic medicine sales and high uptake of biologics. High Potential Active Pharmaceutical Ingredients (HPAPI) are also driving the API market growth globally as these compounds are very effective in treatment of diseases such as cancer, respiratory disorders and hormonal imbalances and HPAPI growth is mainly driven by its therapeutic applications in Oncology. Depending on the product type the API market is segmented into synthetic API, Biotech API, and HPAPI. Synthetic API commanded the largest share in 2013 and is growing at a steady pace, whereas the biotech API is expected to register the highest CAGR during the forecast period, strongly driven by the monoclonal antibodies and recombinant proteins. Depending on the applications the API market is categorized into oncology, cardiovascular and hematopoietic system, central nervous system, anti-infective, gastrointestinal, respiratory system, metabolic disorders, genito-urinary disorders, and others. Cardiovascular commanded the largest share of more than 40% in 2013 and is growing at a steady pace, whereas oncology is expected to register the highest CAGR during the forecast period. HPAPI commanded the largest share in the oncology application segment in 2013 and is growing at a highest CAGR in the anti-infectives segment. Scope of the Report Global API Market, by Synthesis: - Synthetic Chemical API - Branded/Innovative - Generic/Non-branded - Biotech API - Biologics - Biosimilars - Mammalian cell culture - Monoclonal antibodies - Recombinant proteins - Vaccines - Insulin analog - Growth hormone manufacturing - Interferon manufacturing - HPAPI Global API Market, by Business type: - Captive - Merchant Global API Market, by Therapeutic Applications: - Anti-infectives - Oncology - Cardiovascular and hematopoietic system - Central nervous system - Respiratory system - Gastrointestinal disorders - Hormone-related disorders - Metabolic disorders - Genitourinary disorders - Musculo-skeletal disorders - Others Companies Mentioned - Albemarle Corporation - Aurobindo - Boehringer Ingelheim GmbH - Cambrex Corporatio - Dr. Reddy's Lab - Lonza Group - Lupin - Novartis - Ranbaxy Laboratories - Teva Active Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/sm...bal_active
CBM: 21.62 (+0.37), ALB: 60.48 (-0.34), NVS: 93.91 (+0.66)
Cambrex Earnings Review: 18 Days after Announcement Shares Up 11.1% (CBM)
Comtex SmarTrend(R) - Mon Nov 17, 10:50AM CST
18 days ago, on October 30th, 2014, Cambrex (NYSE:CBM) reported its earnings. Analysts, on average, expected earnings of $0.26 per share on sales of $94.2 million. The company actually reported EPS of $0.26 on sales of $81.3 million, beating EPS estimates by $0.00 and missing revenue estimates by $12.9 million. Shares of Cambrex have climbed from $20.86 to $23.17, representing a gain of 11.1% since the company reported earnings 18 days ago.
CBM: 21.62 (+0.37)
Cambrex Shares Up 20.2% Since SmarTrend's Buy Recommendation (CBM)
Comtex SmarTrend(R) - Wed Nov 12, 9:19AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 weeks, Cambrex has returned 20.18% as of today's recent price of $23.14.
CBM: 21.62 (+0.37)
Can the Rally in Cambrex (CBM) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:34AM CST
Can the Rally in Cambrex (CBM) Shares Continue?
CBM: 21.62 (+0.37)
NYSE stocks posting largest percentage increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
DHX: 10.28 (+0.08), HLF: 37.98 (+0.20), CBM: 21.62 (+0.37), ESI: 10.18 (-0.01), JMP: 8.08 (-0.24), THR: 23.68 (+0.12), AU: 8.39 (+0.24), VSLR: 8.97 (+0.18), NLS: 14.58 (-0.17), CCG: 7.58 (-0.05), DAC: 5.50 (-0.03), CVD: 103.73 (+0.02)
Cambrex's (CBM) CEO Steve Klosk on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:36AM CDT
CBM: 21.62 (+0.37)
Cambrex posts 3Q profit
Automated Insights - Thu Oct 30, 8:42AM CDT
E RUTHERFORD, N.J. (AP) _ Cambrex Corp. (CBM) on Thursday reported net income of $8.8 million in its third quarter.
CBM: 21.62 (+0.37)
Cambrex (CBM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT
CBM: 21.62 (+0.37)
Cambrex beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:27AM CDT
CBM: 21.62 (+0.37)
Cambrex Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:00AM CDT
Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2014.
CBM: 21.62 (+0.37)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT
FIS: 63.62 (-0.42), HST: 24.23 (-0.07), CRR: 40.16 (-0.81), CAH: 82.07 (+0.15), AMT: 100.75 (+0.10), ACIW: 20.76 (+0.12), GTI: 4.84 (-0.04), IDA: 67.37 (+1.01), CRCM: 8.12 (+0.14), CVRR: 16.90 (-0.21), BGCP: 9.06 (-0.10), GOV: 23.32 (-0.03), DFT: 33.68 (+0.03), APO: 23.33 (-0.09), FIG: 7.89 (unch), AMAG: 43.02 (+0.90), HAR: 105.30 (+0.11), AVP: 9.22 (-0.07), EXLS: 28.69 (+0.21), INGR: 86.09 (-0.27), ALU: 3.67 (+0.03), INCY: 71.57 (+1.99), COP: 70.13 (-0.92), GEL: 43.39 (-0.65), COR: 38.83 (+0.43), GTLS: 34.61 (+0.14), BWA: 55.67 (-0.72), CARB: 14.54 (+0.94), GLOP: 25.07 (-0.23), IDCC: 54.33 (+0.15), HEES: 28.38 (-0.59), BCO: 24.09 (-0.03), DST: 95.96 (-0.16), EPD: 35.45 (+0.25), ABMD: 38.46 (+0.13), CEVA: 18.37 (+0.56), BLL: 69.70 (-0.14), GBX: 51.59 (+0.47), GNC: 46.10 (-0.29), CVI: 39.62 (unch), ACOR: 39.14 (+0.74), I: 16.83 (+0.19), FCN: 39.23 (-0.16), CRNT: 0.98 (+0.02), DHX: 10.28 (+0.08), BG: 92.03 (-0.33), CME: 90.58 (-2.14), FCH: 10.80 (-0.06), ALLE: 55.73 (+0.05), AUDC: 4.51 (+0.01), APD: 148.58 (unch), DBD: 35.55 (-0.05), HGG: 7.65 (-0.12), CBM: 21.62 (+0.37), CNSL: 28.07 (+0.32), ATK: 113.52 (+0.59), ANR: 1.60 (-0.02), CI: 104.23 (-0.08), ABC: 91.60 (+0.18), GG: 17.67 (+0.49)
Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014
PR Newswire - Tue Oct 28, 2:03PM CDT
Cambrex Corporation (NYSE: CBM) announced that third quarter 2014 financial results will be released on Thursday, October 30, 2014 before the market opens.
CBM: 21.62 (+0.37)
Shares of CBM Down 10.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 22, 11:22AM CDT
SmarTrend identified a Downtrend for Cambrex (NYSE:CBM) on September 23rd, 2014 at $19.89. In approximately 4 weeks, Cambrex has returned 10.61% as of today's recent price of $17.78.
CBM: 21.62 (+0.37)